Pre-Clinical Drug Development Consultancy

$1,000.00

Our pre-clinical drug development consultancy helps biotech and pharma teams de-risk and accelerate their pipelines by integrating state-of-the-art computational chemistry with experimental strategy. We work from target assessment through lead optimization to provide clear, data-driven decisions at every stage.

Scope of Services

  • Target Assessment & Druggability
    Structural and sequence-based analyses to evaluate target druggability, binding pockets, allosteric sites, and competition landscape, supporting early go/no-go decisions before heavy investment.

  • In Silico Hit Identification & Lead Design
    Virtual screening, pharmacophore modeling, molecular docking, and AI/ML-supported design to identify and prioritize high-value hits. We deliver ranked hit lists with binding hypotheses, interaction maps, and synthetic starting points.

  • Lead Optimization & Multi-Parameter Profiling
    Iterative modeling cycles combining docking, molecular dynamics, MM/GBSA and related free-energy methods with in silico ADME/Tox and developability metrics. We help you balance potency, selectivity, safety, and chemical tractability in a rational, quantitative framework.

  • Mechanism & Binding-Mode Elucidation
    Molecular dynamics, enhanced sampling, and conformational landscape analysis to understand binding modes, key interactions, induced fit, allosteric communication, and resistance mechanisms. Outputs are tailored to support medicinal chemistry hypotheses and experimental validation.

  • ADME/Tox & Developability Risk Assessment
    Prediction of solubility, permeability, metabolic stability, CYP and hERG risks, off-target liabilities, and basic PK-relevant properties. We flag liabilities early and propose structure-based mitigation strategies.

  • Portfolio & Decision Support
    Comparative scoring and prioritization across series, targets, or indications, integrating computational readouts with your experimental data. We provide concise, board-ready reports and visualizations to support investment, partnering, and pipeline-focusing decisions.

We operate as an extension of your R&D team, delivering reproducible workflows, transparent methodologies, and publication- or regulatory-ready documentation. Engagements can range from focused feasibility studies to fully integrated pre-clinical support across multiple programs.

Our pre-clinical drug development consultancy helps biotech and pharma teams de-risk and accelerate their pipelines by integrating state-of-the-art computational chemistry with experimental strategy. We work from target assessment through lead optimization to provide clear, data-driven decisions at every stage.

Scope of Services

  • Target Assessment & Druggability
    Structural and sequence-based analyses to evaluate target druggability, binding pockets, allosteric sites, and competition landscape, supporting early go/no-go decisions before heavy investment.

  • In Silico Hit Identification & Lead Design
    Virtual screening, pharmacophore modeling, molecular docking, and AI/ML-supported design to identify and prioritize high-value hits. We deliver ranked hit lists with binding hypotheses, interaction maps, and synthetic starting points.

  • Lead Optimization & Multi-Parameter Profiling
    Iterative modeling cycles combining docking, molecular dynamics, MM/GBSA and related free-energy methods with in silico ADME/Tox and developability metrics. We help you balance potency, selectivity, safety, and chemical tractability in a rational, quantitative framework.

  • Mechanism & Binding-Mode Elucidation
    Molecular dynamics, enhanced sampling, and conformational landscape analysis to understand binding modes, key interactions, induced fit, allosteric communication, and resistance mechanisms. Outputs are tailored to support medicinal chemistry hypotheses and experimental validation.

  • ADME/Tox & Developability Risk Assessment
    Prediction of solubility, permeability, metabolic stability, CYP and hERG risks, off-target liabilities, and basic PK-relevant properties. We flag liabilities early and propose structure-based mitigation strategies.

  • Portfolio & Decision Support
    Comparative scoring and prioritization across series, targets, or indications, integrating computational readouts with your experimental data. We provide concise, board-ready reports and visualizations to support investment, partnering, and pipeline-focusing decisions.

We operate as an extension of your R&D team, delivering reproducible workflows, transparent methodologies, and publication- or regulatory-ready documentation. Engagements can range from focused feasibility studies to fully integrated pre-clinical support across multiple programs.